JPRN-UMIN000002856已完成未知
Phase I/II study of VEGFR1/2-derived peptide vaccination in combination with a 5-fluorouracil derivative (TS-1) for metastatic colorectal cancer with KRAS genetic mutation as a third-line therapy - Phase I/II study of peptide vaccination in combination with TS-1 for metastatic colorectal cancer with KRAS genetic mutation
Devision of Clinical Oncology, Tohoku University Hospital0 个研究点目标入组 15 人开始时间: 2010年1月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. active double cancer(s) 2. undertook radiation therapy for abdominal lesions. 3. HIV-positive patients 4. sever comorbidity (intestinal obstruction, uncontrolled Diabetes M., uncontrolled hypertension, Angina P., liver cirrhosis, pneumonitis, emphysema, etc) 5. allergy for TS1 6. ascites or pleural effusion that needs to be treated 7. patients with bleeding 8. patients treated with fruitosin 9. pregnant woman
研究者
相似试验
招募中
1 期
VEGFR 1/2 Peptide Vaccine for Recurrent, Progressive and Refractory Brain TumorsJPRN-jRCTs031180162Toda Masahiro20
已完成
1 期
Phase 1 & 2 clinical trial using peptide vaccine for VEGFR1 & 2 in combination with S-1 and Cisplatin for patients with advanced gastric cancerunresectable or recurrent gastric cancerJPRN-UMIN000005007Osaka University, Graduate School of Medicine, Department of Gastroenterological Surgery30
已完成
1 期
Phase 1 & 2 clinical trial using peptide vaccine for VEGFR1 & 2 in combination with S-1 and Cisplatin for patients with advanced gastric cancer (HLA-A*0201)JPRN-UMIN000005345Osaka University, Graduate School of Medicine, Department of Gastroenterological Surgery15
招募中
1 期
VEGFR1/2 Peptide Vaccine in Patients with Recurrent, Progressive and Refractory Brain TumorsRecurrent, Progressive and Refractory Brain Tumors(hemangiopericytoma, hemangioblastoma, WHO grade II or III meningioma, chordoma, ependymoma)JPRN-UMIN000029005Keio university school of medicine20
已完成
不适用
Phase II clinical trial of WT1 peptide-based vaccine combined with Temozoromide for patients with glioblastoma.GlioblastomaJPRN-UMIN000026965Department of Cancer Immunotherapy, Osaka University Graduate School of Medicine35